SCHEMBL24512334

SCHEMBL24512334

Cc1ccc(-c2nnc(-c3ccccc3)[nH]2)cc1S(=O)(=O)N1CCN(C2COC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 9/20 0.48
CNR2 P34972 9/20 0.48
MAPT P10636 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
MAPK1 P28482 1/20 0.43
HTT P42858 1/20 0.43
TP53 P04637 1/20 0.42
ALDH1A1 P00352 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
BRD4 O60885 2/20 0.41
BRD2 P25440 2/20 0.41
BRD3 Q15059 2/20 0.41
TSHR P16473 2/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
KMT2A Q03164 1/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29717135 1.00 CNR1 (0.48) CNR1CNR2MAPTSMN1; SMN2KDM4E
SCHEMBL24512359 0.85 CNR1 (0.46) CNR1CNR2MAPTSMN1; SMN2KDM4E
SCHEMBL24512121 0.85 CNR1 (0.46) CNR1CNR2MAPTSMN1; SMN2KDM4E
SCHEMBL29717158 0.85 CNR1 (0.41) CNR1CNR2MAPTSMN1; SMN2KDM4E
SCHEMBL24512243 0.85 CNR1 (0.41) CNR1CNR2MAPTSMN1; SMN2KDM4E
SCHEMBL29717111 0.85 CNR1 (0.64) CNR1CNR2MAPTSMN1; SMN2KDM4E
SCHEMBL24512245 0.85 CNR1 (0.64) CNR1CNR2MAPTSMN1; SMN2KDM4E
SCHEMBL29717142 0.84 LMNA (0.52) CNR1CNR2MAPTSMN1; SMN2LMNA
SCHEMBL29717201 0.84 LMNA (0.55) CNR1CNR2MAPTSMN1; SMN2LMNA
SCHEMBL29717169 0.83 BRD4 (0.54) CNR1CNR2MAPTSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117915903-A Compounds for the treatment of neurodegenerative, degenerative and metabolic disorders and uses thereof 佛罗里达大学研究基金会公司 2024-04-19 CN disclosed
WO-2022125989-A1 COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS SCRIPPS RESEARCH INSTITUTE, THE (US) 2022-06-16 WO disclosed